<PAGE>
Total Number of Pages: 3
--
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: May 5, 2000
Commission File Number: 0-26208
================================================================================
KERAVISION, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 77-0328942
(State of Incorporation) (I.R.S. Employer
Identification No.)
48630 MILMONT DRIVE
FREMONT, CA 94538
(Address of principal executive offices)
(510) 353-3000
(Registrant's telephone number)
<PAGE>
ITEM 5. OTHER EVENTS
On April 27, 2000, KeraVision, Inc. announced two new financing programs
that are designed to make the Intacs technology easier for physicians to
acquire. Further details regarding this announcement are contained in the
Company's news release dated April 27, 2000 attached as exhibit hereto and
incorporated by reference herein.
On May 1, 2000, KeraVision, Inc. announced the Intacs vision correction
technology will be the subject of over a dozen scientific presentations that
are scheduled for this year's American Society of Cataract and Refractive
Surgery (ASCRS) meeting on May 20-24, 2000 in Boston. Further details
regarding this announcement are contained in the Company's news release dated
May 1, 2000, attached as exhibit hereto and incorporated by reference herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Exhibits:
99.39 KeraVision, Inc. News Release dated April 27, 2000
99.40 KeraVision, Inc. News Release dated May 1, 2000
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KERAVISION, INC.
/s/Mark Fischer-Colbrie
-----------------------
Mark Fischer-Colbrie
Vice President, Finance and
Administration and Chief Financial
Officer(Principal Financial and
Accounting Officer)
Date: May 5, 2000
3
<PAGE>
Exhibit 99.39
KeraVision Announces New Financing Options for Intacs Surgeons
Start-up surgeons' kits offered through KeraUse and KeraLease
FREMONT, CA (April 27, 2000) - KeraVision, Inc. (Nasdaq: KERA), developer
of Intacs prescription inserts for correcting mild nearsightedness
(myopia), announced two new financing programs that are designed to make
the Intacs technology easier for physicians to acquire.
The KeraUse program is a "pay as you go" usage arrangement in which the
Intacs technology is acquired over a 39-month period, with the first
payment deferred for three months. To participate, ophthalmic surgeons
must commit to buying at least 216 Intacs inserts, at $697 each, over the
course of the program.
The KeraLease program is a 36-month lease arrangement that offers the
Intacs technology for $1,499 per month. Included are a surgical
instrument set, valued at $36,000, and start-up inventory of 18 Intacs
inserts, valued at $500 each.
As with the company's original purchase plan, surgeon training and
follow-up in-field proctoring are provided at no charge to physicians who
buy or lease the Intacs surgical instrument set.
"The KeraUse and KeraLease programs are designed to remove the cost
barriers to expanding a surgeon's refractive practice into the mainstream
mild myopia segment, which is the segment for which Intacs are especially
designed," said Steve Henderson, KeraVision Vice President - Sales.
"These programs make it easier to become a comprehensive refractive
provider."
Both financing programs provide special incentives to surgeons who
quickly adopt Intacs as part of their practice once they have completed
Intacs training and proctoring.
KeraVision's original purchase program will continue to be offered. This
program provides a "start-up" surgeons' kit consisting of an instrument
set and 18 Intacs inserts, for $45,000.
KeraVision, founded in 1986, is the developer of Intacs prescription
inserts for correcting mild myopia, which was named one of "The Year's
Top 10 Medical Advances" by CNN and Health magazine. Approved by the FDA
in 1999, Intacs are a flexible and convenient option to eyeglasses,
contact lenses and vision correction surgeries that permanently alter the
eye's central optical zone. The company's patented Intacs technology is
also being developed for the possible treatment of hyperopia
(farsightedness); myopia (nearsightedness) in wider ranges than presently
approved by the FDA; astigmatism; and keratoconus, a corneal thinning
disease.
Except for the historical information, the matters discussed in this news
release are forward-looking statements. Actual results may differ
materially due to a variety of factors, including market acceptance of
Intacs prescription inserts, the need for additional capital to fund
future business operations, complications relating to the product or the
surgical procedure, competitive products and technologies, and other risk
factors described under the heading "Risk Factors" contained in Item 1 of
KeraVision's Form 10-K for the year ended December 31, 1999, as well as
in other SEC filings.
Note to Editors: KeraVision and Intacs are registered trademarks or
trademarks of KeraVision, Inc. in the U.S. and foreign countries
For further information
Investors: Mark Fischer-Colbrie, (510) 353-3000
Media: Mick Taylor, (510) 353-3075
www.GetIntacs.com
"Fax On Demand"
(800) 448-8559
<PAGE>
Exhibit 99.40
FOR IMMEDIATE RELEASE
Intacs Prescription Inserts to be Focus of Scientific Presentations May 20-24
KeraVision's R&D programs also to be highlighted
BOSTON, MA (May 1, 2000) - The Intacs vision correction technology will
be the subject of over a dozen scientific presentations that are
scheduled for this year's American Society of Cataract and Refractive
Surgery (ASCRS) meeting on May 20-24, 2000 in Boston.
Developed by KeraVision, Inc. (Nasdaq: KERA), Intacs prescription inserts
are a new, FDA-approved, non-laser option for correcting mild
nearsightedness (myopia), a condition that affects over 20 million adult
Americans, according to industry estimates. In addition, the Intacs
technology is in clinical studies for the possible treatment of
farsightedness (hyperopia), keratoconus (corneal thinning disease),
astigmatism, and a wider range of myopia than currently approved for use
in the U.S. by the FDA.
Presentations on these and other Intacs-related clinical studies are
scheduled for the ASCRS meeting, including:
- -- "Rapid Visual Results with IntacsT" by Steven M. Verity, MD, assistant
professor of ophthalmology, St. Louis University, St. Louis, MO.
- -- "Future Developments in Intacs," Penny A. Asbell, MD, professor of
ophthalmology and director of cornea services, Mount Sinai School of
Medicine, New York.
- -- "Expanding Your Refractive Practice with Intacs" and "Two Technologies
to Correct Myopia: Intacs and LASIK," G. Peyton Neatrour, MD, Beach Eye
Care, Virginia Beach, VA.
- -- "Intacs as an Enhancement after Under-Corrected Myopic LASIK," Andrew
Moyes, MD, Eye Center of Kansas City, Overland Park, KS.
- -- "Improving Outcomes Through Intacs Replacement," Bradley D. Fouraker,
MD, Tampa, FL.
- -- "Intacs Learning Curve: First Year Experience," Michael Mockovak, MD,
Sacramento, CA.
- -- "Intacs In the Real World: How Do They Measure Up?" Vance Thompson,
MD, Ophthalmology Ltd., Sioux Falls, SD.
- -- "Initial Experience with Intacs," Ezra Galler, MD, Providence, RI.
- -- "Ocular and Refractive Changes After the Implantation, Removal and Re-
Implantation of Intacs," Michael Twa, OD, instructor of ophthalmology and
clinical research coordinator, University of California at San Diego, La
Jolla, CA.
- -- "Intacs and LASIK: An Option for High Myopes and Pre-Presbyopic
Patients" and "Intacs and LASIK: Better Quality Vision for High Myopes;
Removal Option for Pre-Presbyopic Patients," by Carlo Lovisolo, MD,
Milan, Italy
The ASCRS meeting is one of the major ophthalmic medical conferences in
the world, each year attracting more than 5,000 attendees from over 70
countries.
KeraVision, founded in 1986, is the developer of Intacs prescription
inserts for correcting mild myopia, which was named one of "The Year's
Top 10 Medical Advances" by CNN and Health magazine. Approved by the FDA
in 1999, Intacs are a flexible and convenient option to eyeglasses,
contact lenses and vision correction surgeries that permanently alter
the eye's central optical zone. The company's patented Intacs
technology is also being developed for the possible treatment of
hyperopia (farsightedness); myopia (nearsightedness) in wider ranges
than presently approved by the FDA; astigmatism; and keratoconus, a
corneal thinning disease.
Except for the historical information, the matters discussed in this news
release are forward-looking statements. Actual results may differ
materially due to a variety of factors, including market acceptance of
Intacs prescription inserts, the need for additional capital to fund
future business operations, complications relating to the product or the
surgical procedure, competitive products and technologies, and other risk
factors described under the heading "Risk Factors" contained in Item 1 of
KeraVision's Form 10-K for the year ended December 31, 1999, as well as
in other SEC filings.
Note to Editors: KeraVision and Intacs are registered trademarks or
trademarks of KeraVision, Inc. in the U.S. and foreign countries
For further information
Investors: Mark Fischer-Colbrie, (510) 353-3000
Media: Mick Taylor, (510) 353-3075
www.GetIntacs.com
"Fax On Demand"
(800) 448-8559
